Tue, Nov 20, 2013
Fri, June 14, 2013
Pharmaceutical Business Review – Mon, June 3, 2013
National Volunteer Fire Council – Tue, May 14, 2013
Cardioviva™ Backlit Display – Mon, April 1, 2013
With ten years of work behind it, two clinical trials (plus results of a third ready for publication), and Groupe Danone on-board, Canada’s Micropharma is rolling out its cholesterol-lowering Lactobacillus reuteri NCIMB 30242 for the US supplement, food and beverage industries.
Montréal, Québec, Oct. 11, 2012 – Over half (52 percent) of supplement users are concerned about their heart health and 73 percent express an interest in natural, clinically proven solutions for healthy cholesterol support, according to market research conducted by Micropharma Limited, a pioneer in the development of innovative and effective probiotics.
Micropharma Limited, a pioneer in the development of innovative and effective probiotics, has filed a number of patents for its probiotic technologies. Probiotics - bacteria that confer a health benefit to the host - are being studied to determine if they may have a more significant role in helping to maintain and improve health and wellness through the gut. And emerging science is evaluating whether supplementing the microbiome (gut bacteria) with probiotics can play a role in health and certain chronic diseases such as heart disease.
Montréal, Québec - Micropharma Limited, a pioneer in the development of innovative and effective probiotics, released the results today of a second gold standard clinical trial evaluating the efficacy of Cardioviva™. The study was aimed at evaluating the cholesterol-lowering efficacy and the mechanism of action of Lactobacillus reuteri NCIMB 30242 (Cardioviva™) capsules in hypercholesterolemic adults. A total of 127 subjects completed a randomized, double-blind, placebo-controlled, parallel-arm, multicenter study.
Montreal, Quebec - In a recent article written by Dr. Mary Ellen Sanders entitled: Update on Cholesterol-Lowering Probiotics published on usprobiotics.org, Dr. Sanders writes "...until recently, there has not been many convincing randomized, controlled trials that document specific probiotic-induced improvements in blood lipids. A recent study suggests that certain probiotics might improve blood lipid profiles. Jones et al. 2012 testes the effect of feeding hypercholesterolemic adults yogurt containing microencapsulated Lactobacillus reuteri NCIMB 30242. A total of 114 subjects, divided between probiotic and placebo group, participated in this study.
Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial.
Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized, double-blindes, placebo controlled study.
Evaluation of safety and tolerance of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation: A randomized, placebo-controlled, double-blind study.